A Study of BMS-986340 as Monotherapy and in Combination With Nivolumab or Docetaxel in Participants With Advanced Solid Tumors
Bristol-Myers Squibb
Bristol-Myers Squibb
Genmab
Aulos Bioscience, Inc.
Ipsen
AstraZeneca
Mayo Clinic
Neonc Technologies, Inc.
Arvinas Inc.
M.D. Anderson Cancer Center
University of California, Davis
Second Life Therapeutics
Onchilles Pharma Inc
Inhibrx Biosciences, Inc
DualityBio Inc.
University of Pittsburgh
ImmVira Pharma Co. Ltd
Palleon Pharmaceuticals, Inc.
Sensei Biotherapeutics, Inc.
Incyte Corporation
Incyte Corporation
MacroGenics
NuCana plc
Medicenna Therapeutics, Inc.
Marengo Therapeutics, Inc.
NGM Biopharmaceuticals, Inc
OncoC4, Inc.
Mural Oncology, Inc
Rapa Therapeutics LLC
Xynomic Pharmaceuticals, Inc.
Kymab Limited
BioAtla, Inc.
Purple Biotech Ltd.
Aminex Therapeutics, Inc.
CJ Bioscience, Inc.
Simcha IL-18, Inc.
Salubris Biotherapeutics Inc
NGM Biopharmaceuticals, Inc
GlaxoSmithKline
Pfizer
iTeos Therapeutics
Innolake Biopharm
GeneMedicine Co., Ltd.
NextCure, Inc.
Erasmus Medical Center
OncoResponse, Inc.
Rain Oncology Inc
Genmab
Kineta Inc.
Nektar Therapeutics
Rubius Therapeutics